Skip to main content Skip to main navigation Skip to search Skip to footer

HCL Technologies

Transforming Clinical Development

Transforming Clinical Development

R&D spend has tripled, the number of new drugs approved by FDA have reduced to 30%, thus increasing the pressure on pharmaceutical industry to bring in efficiencies in every process. Site monitoring constitutes 45% of the annual Clinical Trials expenditure in the R&D spend for a typical Pharma. It is now imperative to target on-site monitoring of clinical trials by identifying centers with anomalous and inconsistent data.

Contact Us
MAX CHARACTERS: 10,000

We will treat any information you submit with us as confidential.

We will treat any information you submit with us as confidential.